Related Experiment Video
Updated: Jul 11, 2026
07:20
Studies on the Anti-Inflammatory Effect of Xiaoyao Pills in The Treatment of Postmenopausal Osteoporosis in Mice
Published on: August 23, 2024
Emerging pharmacologic therapies for osteoporosis
1University of Auckland, Department of Medicine, Auckland, New Zealand. a.grey@auckland.ac.nz
Expert Opinion on Emerging Drugs
|September 19, 2007
Summary
Osteoporotic fractures pose a significant public health challenge. New treatments targeting bone resorption and promoting bone formation offer improved strategies for preventing fragility fractures in an aging population.
Area of Science:
- Orthopedics
- Pharmacology
- Gerontology
Background:
- Osteoporotic fractures are a major cause of morbidity and mortality in aging populations.
- Current pharmacologic therapies for fragility fractures have limitations in efficacy and patient acceptance.
- There is a critical need for novel and improved osteoporosis treatments.
Purpose of the Study:
- To review current and emerging pharmacologic therapies for the prevention of osteoporotic fractures.
- To highlight advancements in both antiresorptive and anabolic approaches to osteoporosis treatment.
- To discuss novel molecular targets for future osteoporosis therapies.
Main Methods:
- Review of existing literature on osteoporosis pharmacotherapy.
- Analysis of novel drug classes targeting osteoclastic bone resorption.
- Examination of anabolic agents and their mechanisms of action, including parathyroid hormone (PTH) therapy.
Main Results:
- Several drug classes inhibit osteoclastic bone resorption, including bisphosphonates and cathepsin K inhibitors.
- Parathyroid hormone (PTH) therapy demonstrates the efficacy of osteoblast-targeted (anabolic) agents in preventing fractures.
- Emerging therapies target pathways like Wnt signaling and sclerostin for enhanced bone anabolism.
Conclusions:
- A growing number of pharmacologic options are available for osteoporosis management.
- Both antiresorptive and anabolic strategies are crucial for effective fracture prevention.
- Future research focuses on novel anabolic agents and molecular targets to further optimize osteoporosis treatment.
Related Concept Videos
01:29Bone Disorders
Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
01:31Osteoclasts in Bone Remodeling
Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during bone...
01:28Drug Therapy
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
01:40Bone Remodeling
Bone remodeling is a continuous and balanced process of bone resorption by osteoclasts and bone formation by osteoblasts. In adults, it helps maintain bone mass and calcium homeostasis. While mechanical stress can stimulate turnover as part of the normal maintenance and reparative process, several hormones also regulate bone remodeling.
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...